|
業務類別
|
Biotechnology |
|
業務概覽
|
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeuticproteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases. |
| 公司地址
| 9804 Medical Center Drive, Rockville, MD, USA, 20850 |
| 電話號碼
| +1 240 552-8181 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.regenxbio.com |
| 員工數量
| 371 |
| Mr. Craig Malzahn |
Executive Vice President, Product Development and Chief Technology Officer |
-- |
14/04/2026 |
| Mr. Mitchell Chan |
Executive Vice President, Chief Financial Officer, Treasurer and Principal Accounting Officer |
-- |
14/04/2026 |
| Mr. Stephen Pakola, M.D. |
Executive Vice President and Chief Medical Officer |
美元 543.99K |
14/04/2026 |
| Dr. Olivier Danos, PhD |
Executive Vice President and Chief Scientific Officer |
-- |
14/04/2026 |
| Mr. Patrick J. Christmas |
Executive Vice President, Chief Strategy Officer and Chief Legal Officer |
美元 520.90K |
14/04/2026 |
| Mr. Curran Simpson |
Director, President and Chief Executive Officer |
美元 665.51K |
14/04/2026 |
|
|
| Ms. Jennifer Zachary |
Independent Director |
14/04/2026 |
| Dr. Jean Bennett, M.D.,Pd.D |
Independent Director |
14/04/2026 |
| Mr. Allan M. Fox |
Independent Director |
14/04/2026 |
| Dr. Alexandra Glucksmann, PhD |
Independent Director |
14/04/2026 |
| Mr. Daniel Tasse |
Lead Independent Director |
14/04/2026 |
| Mr. George V. Migausky |
Independent Director |
14/04/2026 |
| Dr. David C. Stump,M.D. |
Independent Director |
14/04/2026 |
| Mr. Curran Simpson |
Director, President and Chief Executive Officer |
14/04/2026 |
| Mr. Kenneth T. Mills |
Chairman of the Board |
14/04/2026 |
| Dr. Argeris N. Karabelas, PhD |
Independent Director |
14/04/2026 |
|
|
|
|
